Related Experiment Video

Updated: May 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pleiotropic and Lipid-lowering Effects of Statins in Hypertension

Lulzim Selim Kamberi1, Aurora Bedri Bakalli, Norma Muhamet Budima

  • 1University Clinical Centre of Kosova, Prishtina, Kosovo.

Materia Socio-Medica
|May 17, 2013
PubMed

Insights

Statins, when used with antihypertensives, significantly reduced blood pressure and aortic atherosclerotic plaques in severe hypertension patients. This suggests statins offer benefits beyond cholesterol reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Conflicting data exists on statins' blood pressure-lowering effects in hypertensive patients.
  • Statins may possess direct blood pressure-lowering capabilities, a pleiotropic effect beyond cholesterol reduction.

Purpose of the Study:

  • To investigate the role of statins as an adjunct therapy in severe hypertension patients with advanced aortic atherosclerotic plaques.
  • To evaluate the impact of statins on blood pressure and plaque reduction in this patient cohort.

Main Methods:

  • A study involving 62 patients with severe hypertension and aortic atherosclerotic plaques was conducted.
  • Patients were divided into two groups: Group A (antihypertensives + statins) and Group B (antihypertensives only).
  • Transesophageal echocardiography was used for plaque assessment at baseline and 12 months.

Main Results:

  • 52.6% of patients in Group A showed significant atherosclerotic plaque reduction compared to 4.1% in Group B.
  • Statins users experienced significantly greater reductions in both systolic and diastolic blood pressure compared to non-users.
  • The difference in plaque reduction between the two groups was highly significant.

Conclusions:

  • Combining statins with antihypertensives in hypertensive patients with aortic plaques leads to greater blood pressure reduction than antihypertensives alone.
  • Statins demonstrate a significant role in managing severe hypertension and associated atherosclerotic plaques.
Abstract

Keywords:
atherosclerotic aortic plaquehypertensionpleiotropic effects of statin.statins

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...